Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis

Abstract As evidence is inconsistent and based on either isolated Asian or Western studies, we conducted a network meta-analysis (NMA) to examine efficacy and safety of 5-FU (5-fluorouracil), capecitabine and S-1-based first-line treatment of advanced esophagogastric cancer in Asian and Western pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Emil ter Veer, Lok Lam Ngai, Gert van Valkenhoef, Nadia Haj Mohammad, Maarten C. J. Anderegg, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6c08bd1fa40642d29a1af0f009d77425
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c08bd1fa40642d29a1af0f009d77425
record_format	dspace
spelling	oai:doaj.org-article:6c08bd1fa40642d29a1af0f009d774252021-12-02T15:05:04ZCapecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis10.1038/s41598-017-07750-32045-2322https://doaj.org/article/6c08bd1fa40642d29a1af0f009d774252017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07750-3https://doaj.org/toc/2045-2322Abstract As evidence is inconsistent and based on either isolated Asian or Western studies, we conducted a network meta-analysis (NMA) to examine efficacy and safety of 5-FU (5-fluorouracil), capecitabine and S-1-based first-line treatment of advanced esophagogastric cancer in Asian and Western patients. Medline, EMBASE, CENTRAL and conferences ASCO and ESMO were searched up to January 2016 for randomized-controlled-trials comparing 5-FU, capecitabine or S-1-based regimens with equal chemotherapy backbones. Direct and indirect data for overall survival (OS) and progression-free-survival (PFS) were combined on the Hazard Ratio (HR)-scale using random-effects NMA and calculated as combined HRs and 95%credible intervals (95%CrI). Grade 1-2 and grade 3-4 adverse events were compared with pair-wise meta-analysis. Fifteen studies were identified including capecitabine (n = 945), 5-FU (n = 2,132) or S-1 (n = 1,636). No differences were found in respectively OS and PFS for capecitabine-based versus 5-FU-based regimens (HR = 0.89, 95%CrI = 0.76–1.04 and HR = 0.98, 95%CrI = 0.75–1.32), S-1-based versus 5-FU-based regimens (HR = 0.92, 95%CrI = 0.82–1.04 and HR = 0.88, 95%CrI = 0.70–1.11) and S-1-based versus capecitabine-based regimens (HR = 1.03, 95%CrI = 0.87–1.22 and HR = 0.89, 95%CrI = 0.65–1.20). Effects were similar in Asian and Western subgroups. Toxicity profiles were different but a lower frequency of relevant adverse events was observed with S-1 In conclusion, as efficacy was similar, choosing fluoropyrimidines should be based on their individual toxicity profiles.Emil ter VeerLok Lam NgaiGert van ValkenhoefNadia Haj MohammadMaarten C. J. AndereggMartijn G. H. van OijenHanneke W. M. van LaarhovenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Emil ter Veer Lok Lam Ngai Gert van Valkenhoef Nadia Haj Mohammad Maarten C. J. Anderegg Martijn G. H. van Oijen Hanneke W. M. van Laarhoven Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
description	Abstract As evidence is inconsistent and based on either isolated Asian or Western studies, we conducted a network meta-analysis (NMA) to examine efficacy and safety of 5-FU (5-fluorouracil), capecitabine and S-1-based first-line treatment of advanced esophagogastric cancer in Asian and Western patients. Medline, EMBASE, CENTRAL and conferences ASCO and ESMO were searched up to January 2016 for randomized-controlled-trials comparing 5-FU, capecitabine or S-1-based regimens with equal chemotherapy backbones. Direct and indirect data for overall survival (OS) and progression-free-survival (PFS) were combined on the Hazard Ratio (HR)-scale using random-effects NMA and calculated as combined HRs and 95%credible intervals (95%CrI). Grade 1-2 and grade 3-4 adverse events were compared with pair-wise meta-analysis. Fifteen studies were identified including capecitabine (n = 945), 5-FU (n = 2,132) or S-1 (n = 1,636). No differences were found in respectively OS and PFS for capecitabine-based versus 5-FU-based regimens (HR = 0.89, 95%CrI = 0.76–1.04 and HR = 0.98, 95%CrI = 0.75–1.32), S-1-based versus 5-FU-based regimens (HR = 0.92, 95%CrI = 0.82–1.04 and HR = 0.88, 95%CrI = 0.70–1.11) and S-1-based versus capecitabine-based regimens (HR = 1.03, 95%CrI = 0.87–1.22 and HR = 0.89, 95%CrI = 0.65–1.20). Effects were similar in Asian and Western subgroups. Toxicity profiles were different but a lower frequency of relevant adverse events was observed with S-1 In conclusion, as efficacy was similar, choosing fluoropyrimidines should be based on their individual toxicity profiles.
format	article
author	Emil ter Veer Lok Lam Ngai Gert van Valkenhoef Nadia Haj Mohammad Maarten C. J. Anderegg Martijn G. H. van Oijen Hanneke W. M. van Laarhoven
author_facet	Emil ter Veer Lok Lam Ngai Gert van Valkenhoef Nadia Haj Mohammad Maarten C. J. Anderegg Martijn G. H. van Oijen Hanneke W. M. van Laarhoven
author_sort	Emil ter Veer
title	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
title_short	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
title_full	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
title_fullStr	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
title_full_unstemmed	Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
title_sort	capecitabine, 5-fluorouracil and s-1 based regimens for previously untreated advanced oesophagogastric cancer: a network meta-analysis
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/6c08bd1fa40642d29a1af0f009d77425
work_keys_str_mv	AT emilterveer capecitabine5fluorouracilands1basedregimensforpreviouslyuntreatedadvancedoesophagogastriccanceranetworkmetaanalysis AT loklamngai capecitabine5fluorouracilands1basedregimensforpreviouslyuntreatedadvancedoesophagogastriccanceranetworkmetaanalysis AT gertvanvalkenhoef capecitabine5fluorouracilands1basedregimensforpreviouslyuntreatedadvancedoesophagogastriccanceranetworkmetaanalysis AT nadiahajmohammad capecitabine5fluorouracilands1basedregimensforpreviouslyuntreatedadvancedoesophagogastriccanceranetworkmetaanalysis AT maartencjanderegg capecitabine5fluorouracilands1basedregimensforpreviouslyuntreatedadvancedoesophagogastriccanceranetworkmetaanalysis AT martijnghvanoijen capecitabine5fluorouracilands1basedregimensforpreviouslyuntreatedadvancedoesophagogastriccanceranetworkmetaanalysis AT hannekewmvanlaarhoven capecitabine5fluorouracilands1basedregimensforpreviouslyuntreatedadvancedoesophagogastriccanceranetworkmetaanalysis
_version_	1718388960250560512

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis

Ejemplares similares